ALLO: Allogene Therapeutics Inc

1.13 USD 0.05 (4.24%)

Setor: Cuidados de saúde Base: US Dollar Moeda de lucro: US Dollar

A taxa do ALLO para hoje mudou para -4.24%. Paralelamente, o preço mais baixo no mercado atingiu 1.11 e o mais alto foi 1.20.

Veja a dinâmica do par de moedas Allogene Therapeutics Inc. As cotações em tempo real ajudam a reagir rapidamente aos movimentos do mercado. Ao alternar entre os diferentes períodos de tempo, você pode monitorar tendências e movimentos de preços por minuto, hora, dia, semana ou mês. Use estas informações para prever os movimentos do mercado e tomar decisões de negociação informadas.

Tela cheia

ALLO Notícias

21:43 Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
19:02 Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO)
15:11 Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
01:13 Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
22:09 Allogene Q2 Cash Tops $300 Million
22:02 Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts
18:37 Allogene stock continues ALPHA3 trial with standard FC regimen after safety event
18:35 Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment
11:47 This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics (NASDAQ:ALLO), AvalonBay Communities (NYSE:AVB)
16:52 Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Allogene Therapeutics (NASDAQ:ALLO)
12:33 Adicet Bio stock rating initiated at Buy by H.C. Wainwright
13:41 Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
00:26 Allogene Therapeutics at Jefferies Conference: Delays and Optimism
21:42 Citi maintains buy rating on Allogene stock following ASCO data
11:44 H.C. Wainwright maintains buy rating on Allogene stock after ASCO update
14:56 Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
09:50 Citizens JMP highlights key ASCO presentations
19:37 Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
13:43 Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner
00:01 Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy
12:40 Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
21:25 Allogene shares update on CAR T-cell therapies at ASCO meeting
13:00 Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays
07:50 Abrdn Life Sciences Investors Q4 2024 Commentary (NYSE:HQL)

Faixa diária

1.11 1.20

Faixa anual

0.86 3.78

Fechamento anterior: 1.18
Open: 1.18

Bid: 1.13
Ask: 1.43

Low: 1.11
High: 1.20

Volume: 1.878 K

Mudança diária: -4.24%
Mudança mensal: -5.83%

Mudança de 6 meses: -39.25%
Mudança anual: -56.37%

30 agosto, sábado